Finanzen von Neuphoria Therapeutics Inc (NEUP)NEUPNeuphoria Therapeutics Inc

Evaluating the bottom line, Neuphoria Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -62.90%, provide a clear picture of how effectively NEUP converts its operational activities into shareholder value.

In the context of the broader market, NEUP competes directly with industry leaders such as COCP and QCLS. With a market capitalization of $20.32M, it holds a significant position in the sector. When comparing efficiency, NEUP's gross margin of N/A stands against COCP's 100.00% and QCLS's N/A. Such benchmarking helps identify whether Neuphoria Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Neuphoria's financial performance shows volatility, with a significant net income of 11,262,161 in Q3 2025 but subsequent losses, including -9,906,504 in Q1 2026. The gross margin was 100% in Q2 and Q3 of 2025 but has since dropped to 0%.